517859 Development of a Kynureninase Clinical Candidate, a First-in-Class Enzymatic Checkpoint Inhibitor

John Blazeck1, Catrina Somody2, Ahlam Qerqez2, Kyle Ford2, Kendra Garrison3, Christos Karamitros3, Everett Stone4 and George Georgiou5, (1)Department of Chemical Engineering, University of Texas at Austin, Austin, TX, (2)Chemical Engineering, UT Austin, Austin, TX, (3)University of Texas at Austin, (4)Molecular Biosciences, University of Texas at Austin, Austin, TX, (5)Department of Chemical Engineering, The University of Texas at Austin, Austin, TX
See more of this Session: Immunotherapy Applications
See more of this Group/Topical: Topical Conference: Immunotherapy